Lauren Julia Brown (@laurenjbrown.bsky.social)

A discussion on our recent publication in @jtoonline.bsky.social. Further studies required to identify the best populations for RT at oligoprogression, but should still be discussed with NSCLC who have limited progression on 1L ICIs. www.jtocrr.org/article/S266... #lcsm

loading . . .

A Response Letter to Kosaka et al. Regarding Manuscript Titled: “Radiotherapy Improves Survival in Non–Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study” Kosaka et al.1 present an important perspective regarding our manuscript “Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.”2 In our study, the median progression-free survival (PFS)-2 was 17 months (95% confidence interval: 12–31) following radiotherapy for oligoprogression in metastatic NSCLC. By contrast, the CURB trial by Tsai et al.3 reported a shorter median PFS of 10 months (95% confidence interval: 7.2–not reached) after stereotactic body radiation therapy (SBRT). https://www.jtocrr.org/article/S2666-3643(24)00137-1/fulltext